SEARCH

SEARCH BY CITATION

References

  • 1
    London CA, Hannah AL, Zadovoskaya R, Chien MB, Kollias-Baker C, Rosenberg M, Downing S, Post G, Boucher J, Shenoy N, Mendel DB and Cherrington JM. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs wtih spontaneous malignancies. Clinical Cancer Research 2003; 9: 27552768.
  • 2
    London CA, Malpas PB, Wood-Follis SL, Boucher JF, Rusk AW, Rosenberg MP, Henry CJ, Mitchener KL, Klein MK, Hintermeister JG, Bergman PJ, Couto GC, Mauldin GN and Michels GM. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clinical Cancer Research 2009; 15: 38563865.
  • 3
    Pryer NK, Lee LB, Zadovaskaya R, Yu X, Sukbuntherng J, Cherrington JM and London CA. Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors. Clinical Cancer Research 2003; 9: 57295734.
  • 4
    Chow LQ and Eckhardt SG. Sunitinib: from rational design to clinical efficacy. Journal of Clinical Oncology 2007; 25: 884896.
  • 5
    Mena AC, Pulido EG and Guillen-Ponce C. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib. Anticancer Drugs 2010; 21(Suppl. 1): S3S11.
  • 6
    Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G and Cherrington JM. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clinical Cancer Research 2003; 9: 327337.
  • 7
    Potapova O, Laird AD, Nannini MA, Barone A, Li G, Moss KG, Cherrington JM and Mendel DB. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Molecular Cancer Therapeutics 2006; 5: 12801289.
  • 8
    Gan HK, Seruga B and Knox JJ. Sunitinib in solid tumors. Expert Opinion on Investigational Drugs 2009; 18: 821834.
  • 9
    Papaetis GS and Syrigos KN. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. BioDrugs 2009; 23: 377389.
  • 10
    Polyzos A. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors. Journal of Steroid Biochemistry and Molecular Biology 2008; 108: 261266.
  • 11
    Cakir M and Grossman AB. Medullary thyroid cancer: molecular biology and novel molecular therapies. Neuroendocrinology 2009; 90: 323348.
  • 12
    Catalano MG, Poli R, Pugliese M, Fortunati N and Boccuzzi G. Emerging molecular therapies of advanced thyroid cancer. Molecular Aspects of Medicine 2010; 31: 215226.
  • 13
    O'Neill CJ, Oucharek J, Learoyd D and Sidhu SB. Standard and emerging therapies for metastatic differentiated thyroid cancer. Oncologist 2010; 15: 146156.
  • 14
    Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ and Brose MS. Phase II trial of sorafenib in advanced thyroid cancer. Journal of Clinical Oncology 2008; 26: 47144719.
  • 15
    Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE Jr, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M and Shah MH. Phase II trial of sorafenib in metastatic thyroid cancer. Journal of Clinical Oncology 2009; 27: 16751684.
  • 16
    Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, Hall NC, Wakely PE Jr, Vasko VV, Saji M, Snyder PJ, Wei L, Arbogast D, Collamore M, Wright JJ, Moley JF, Villalona-Calero MA and Shah MH. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. Journal of Clinical Oncology 2010; 28: 23232330.
  • 17
    Dawson SJ, Conus NM, Toner GC, Raleigh JM, Hicks RJ, McArthur G and Rischin D. Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. Anticancer Drugs 2008; 19: 547552.
  • 18
    Christopoulos A, Ahn SM, Klein JD and Kim S. Biology of vascular endothelial growth factor and its receptors in head and neck cancer: beyond angiogenesis. Head and Neck 2010; doi:10.1002/hed.21588.
  • 19
    Neuchrist C, Erovic BM, Handisurya A, Fischer MB, Steiner GE, Hollemann D, Gedlicka C, Saaristo A and Burian M. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck. Head and Neck 2003; 25: 464474.
  • 20
    Neuchrist C, Erovic BM, Handisurya A, Steiner GE, Rockwell P, Gedlicka C and Burian M. Vascular endothelial growth factor receptor 2 (VEGFR2) expression in squamous cell carcinomas of the head and neck. Laryngoscope 2001; 111: 18341841.
  • 21
    Elser C, Siu LL, Winquist E, Agulnik M, Pond GR, Chin SF, Francis P, Cheiken R, Elting J, McNabola A, Wilkie D, Petrenciuc O and Chen EX. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. Journal of Clinical Oncology 2007; 25: 37663773.
  • 22
    Fountzilas G, Fragkoulidi A, Kalogera-Fountzila A, Nikolaidou M, Bobos M, Calderaro J, Andreiuolo F and Marselos M. A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer. Cancer Chemotherapy and Pharmacology 2010; 65: 649660.
  • 23
    Pasquier E, Kavallaris M and Andre N. Metronomic chemotherapy: new rationale for new directions. Nature Reviews: Clinical Oncology 2010; 7: 455465.
  • 24
    Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R, Shaked Y, Mancuso P, Goldhirsch A, Rocca A, Pietri E and Colleoni M. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. Journal of Clinical Oncology 2008; 26: 48994905.
  • 25
    Garcia-Saenz JA, Martin M, Calles A, Bueno C, Rodriguez L, Bobokova J, Custodio A, Casado A and Diaz-Rubio E. Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline- and taxane-refractory breast cancer. Journal of Chemotherapy 2008; 20: 632639.
  • 26
    Krzyzanowska MK, Tannock IF, Lockwood G, Knox J, Moore M and Bjarnason GA. A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma. Cancer Chemotherapy and Pharmacology 2007; 60: 135141.
  • 27
    Stempak D, Gammon J, Halton J, Moghrabi A, Koren G and Baruchel S. A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors. Journal of Pediatric Hematology/Oncology 2006; 28: 720728.
  • 28
    Sahora A and Khanna C. A survey of evidence in the Journal of Veterinary Internal Medicine oncology manuscripts from 1999 to 2007. Journal of Veterinary Internal Medicine 2010; 24: 5156.